ReviewOncogene2003
Death receptors and melanoma resistance to apoptosis.
Review in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 210 citations in OpenAlex.
- A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.Investigational new drugs · 2006Trial
- Role of phloretin as a sensitizer to TRAIL-induced apoptosis in colon cancer.Oncology letters · 2022Article
- Immunosuppressive Roles of Galectin-1 in the Tumor Microenvironment.Biomolecules · 2021Review
- Anti-Proliferative, Pro-Apoptotic, Anti-Migrative and Tumor-Inhibitory Effects and Pleiotropic Mechanism of Theaflavin on B16F10 Melanoma Cells.OncoTargets and therapy · 2021Article
- Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- RIG-I Has a Role in Immunity AgainstFrontiers in immunology · 2020Article
- Reduced CTL motility and activity in avascular tumor areas.Cancer immunology, immunotherapy : CII · 2019Article
- Autophagy inhibitors regulate TRAIL sensitivity in human malignant cells by targeting the mitochondrial network and calcium dynamics.International journal of oncology · 2019Article
- Tumor necrosis factor-related apoptosis-inducing ligand inhibits the growth and aggressiveness of colon carcinoma via the exogenous apoptosis signaling pathway.Experimental and therapeutic medicine · 2019Article
- Cold PSM, but not TRAIL, triggers autophagic cell death: A therapeutic advantage of PSM over TRAIL.International journal of oncology · 2018Article
- Plasma-stimulated medium kills TRAIL-resistant human malignant cells by promoting caspase-independent cell death via membrane potential and calcium dynamics modulation.International journal of oncology · 2018Article
- Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells.Molecules (Basel, Switzerland) · 2018Article
- The inhibitory effects of compound Muniziqi granule against B16 cells and harmine induced autophagy and apoptosis by inhibiting Akt/mTOR pathway.BMC complementary and alternative medicine · 2017Article
- Bcl‑2 associated athanogene 4 promotes proliferation, migration and invasion of gastric cancer cells.Molecular medicine reports · 2017Article
- Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.Cancer biology & therapy · 2017Review
- Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology.Oncology reviews · 2017Review
- The Hydrogen Sulfide Releasing Molecule Acetyl Deacylasadisulfide Inhibits Metastatic Melanoma.Frontiers in pharmacology · 2017Article
- RACK1 promotes hepatocellular carcinoma cell survival via CBR1 by suppressing TNF-α-induced ROS generation.Oncology letters · 2016Article
- Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity.Cell death & disease · 2016Article
- Ethanol Extract of Oldenlandia diffusa - an Effective Chemotherapeutic for the Treatment of Colorectal Cancer in Humans: -Anti-Cancer Effects of Oldenlandia diffusa.Journal of pharmacopuncture · 2016Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Impaired ability to undergo programmed cell death in response to a wide range of external stimuli acquires melanomas a selective advantage for progression and metastasis as well as their notorious resistance to therapy. Better understanding of mechanisms that govern apoptosis has enabled identification of diverse routes by which melanomas manage to escape stimuli of apoptosis. Changes at genomic, transcriptional and post-translational levels of G-proteins and protein kinases (Ras, B-Raf) and their transcription factor effectors (c-Jun, ATF2, Stat3 and NF-kappaB) affects TNF, Fas and TRAIL receptors, which play important roles in acquiring melanoma's resistance to apoptosis. Here, we summarize our current understanding of changes that alters the regulation of death receptors during melanoma development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.